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Mortality and cancer incidence were studied in the National Registry for Radiation Workers in, relative to earlier analyses, an enlarged
cohort of 174541 persons, with longer follow-up (to 2001) and, for the first time, cancer registration data. SMRs for all causes and all
malignant neoplasms were 81 and 84 respectively, demonstrating a ‘healthy worker effect’. Within the cohort, mortality and incidence
from both leukaemia excluding CLL and the grouping of all malignant neoplasms excluding leukaemia increased to a statistically
significant extent with increasing radiation dose. Estimates of the trend in risk with dose were similar to those for the Japanese
A-bomb survivors, with 90% confidence intervals that excluded both risks more than 2–3 times greater than the A-bomb values and
no raised risk. Some evidence of an increasing trend with dose in mortality from all circulatory diseases may, at least partly, be due to
confounding by smoking. This analysis provides the most precise estimates to date of mortality and cancer risks following occupational
radiation exposure and strengthens the evidence for raised risks from these exposures. The cancer risk estimates are consistent with
values used to set radiation protection standards.
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Estimates of the long-term health risks from ionising radiation are
based largely on studies of the survivors of the atomic bombings in
Japan and of groups exposed for medical reasons (NRC, 2006;
ICRP, 2007; UNSCEAR, 2008). In view of the desirability of
obtaining data relevant to protracted or low-dose radiation
exposures, the National Radiological Protection Board (now the
Radiation Protection Division of the Health Protection Agency)
started the National Registry for Radiation Workers (NRRW) in
1976. Two earlier NRRW analyses (Kendall et al, 1992; Muirhead
et al, 1999a,b) found a strong ‘Healthy Worker Effect’ (HWE).
When cancer mortality was analysed in relation to external
radiation dose, the data were consistent both with existing
radiation risk estimates and – for the most part – with the
absence of an association. However, after excluding CLL which
may not be radiation-inducible (UNSCEAR, 2008), there was
borderline evidence in the second analysis (NRRW-2) of an
increasing trend with dose in leukaemia mortality.
This paper summarises a third analysis (NRRW-3) that provides
more precise information on the risks of occupational radiation
exposure based on cancer registrations as well as mortality, data
from an enlarged cohort of 174541 workers, and a further 9 years
of follow-up relative to NRRW-2. Further details are given by
Muirhead et al (2009).
MATERIALS AND METHODS
Definition of cohort
The study population contains persons occupationally exposed to
ionising radiation and for whom radiation dose records were kept.
Data collected from employers consist of individual identifiers,
factors such as date of birth, gender and industrial classification,
and radiation dose histories. These data were audited prior to their
inclusion in the analysis. Table 1 shows the study population by
first employer and lifetime dose. All of these employers were
included in NRRW-2. For some employers, the cohort is restricted
to persons who undertook radiation work on or after 1 January
1976, when the NRRW was set up. However, earlier radiation
workers are included in most instances. The NRRW-3 cohort
contains about 50000 more workers than before, namely:
(i) for most employers, persons who started radiation work
during 1991–1999;
(ii) workers who ceased employment at BNFL Capenhurst and
Springfields before 1976;
(iii) Ministry of Defence radiation workers who ceased employ-
ment before 1977;
(iv) workers at British Energy Generation/Magnox Electric’s
Dungeness A and B power stations during 1965–1990.
Radiation workers are given the opportunity to refuse to
participate in the NRRW. The refusal rate varied across organisa-
tions, but overall it was only about 1%.
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radiation at the surface of the body, estimated using personal
dosemeters. Most of the doses are associated with X-rays and
g-rays, together – to a lesser extent – with b particles and neutrons.
As doses were recorded primarily to ensure compliance with dose
limits or constraints, corrections were applied to arrive at more
accurate dose estimates (Muirhead et al, 1999b). The collective
external dose was 4348 person Sv (Table 1), compared with 3810
person Sv from NRRW-2. The mean lifetime dose was 24.9mSv
overall, but varied considerably between employers. Six percent of
workers had a lifetime dose of 100mSv or more; they contributed
59% of the collective dose. Estimates of doses from internal
emitters (i.e., radionuclides which have been inhaled or ingested)
were not generally available and could not be used here, but
workers monitored for potential exposure were identified.
The distribution of year of birth peaked between the late 1940s
and the early 1960s (Muirhead et al, 2009). Just fewer than 10% of
all workers were female; they tended to be born later than male
workers and to have lower mean lifetime doses.
Follow-up
Information on mortality, cancer registrations and emigrations
was obtained from the NHS Central Registers (NHSCRs) for
England and Wales and for Scotland, plus regional offices covering
other parts of Britain and Ireland. Vital status checks were
conducted at the Department for Work and Pensions and cross-
checks were undertaken together with other research groups
(Muirhead et al, 2009).
The end of follow-up was 31 December 2001. This date was
chosen to ensure that complete personal and dose information was
available up to at least 2 years previously, as 2 years was the
shortest lag period used in the radiation analyses. At the end of
follow-up, 28320 out of the 174541 cohort members were recorded
as having died, 4579 were recorded as having emigrated and 1036
could not be traced satisfactorily.
Statistical methods
The methods are similar to those used previously. The start of
follow-up for each worker was the latest of: the date of start of
radiation work with a participating employer (plus, in some
instances, a lag of 2 or 10 years), the date from which full dose data
were available, or 1 January 1955. The end of follow-up was the
date of death or emigration (or cancer registration for the
incidence analysis), the worker’s 85th birthday, or 1 January
2002, whichever was earliest.
The analysis consisted of two parts:
External analysis: Mortality was compared with rates for the
general population of England and Wales by calculating standar-
dised mortality ratios (SMRs), expressed as percentages. Thus an
SMR of 100 denotes equality with national rates. Tests for trends
and heterogeneity in SMRs were based on w
2 statistics (Breslow
and Day, 1987). The external analysis was based on the underlying
cause of death, coded according to the International Classification
of Diseases (ICD)’s 9th revision (WHO, 1977). For disease
groupings whose ICD codes varied between revisions, rates were
bridge-coded. Mortality rates specific to social classes I and III
were used in analyses of non-industrial and industrial workers,
respectively. The external analysis was performed only for
mortality, as cancer incidence, being based on a combination of
registration and mortality data (see below), could not be compared
with national cancer registration rates.
Internal analysis: Because of a likely HWE, greater emphasis was
placed on analyses internal to the cohort. Mortality and cancer
incidence were studied in relation to dose after adjusting – through
stratification – for age (in 5-year groups), gender, calendar period
(1955-, 1960-, y, 1995, 2000–2001), industrial classification
(industrial/non-industrial/unknown) and first employer (see Muir-
head et al, 2009). Within each stratum, the number of deaths or
cases expected in each category for cumulative external dose
(0 ,1 0  ,2 0  ,5 0  , 100 , 200 , 400þ mSv) was calculated,
conditional on the total over all dose categories and presuming no
effect of dose. To allow for a latent period in any radiation effect
and a particularly strong HWE soon after starting work, the first 2
years of follow-up following initial exposure were excluded when
analysing leukaemia whereas the first 10 years were excluded for
other cancers and deaths; doses were also lagged by 2 and 10 years
respectively. Other lag periods were considered (Muirhead et al,
2009).
Following the lag period, the excess relative risk (ERR) – that is,
the relative risk minus one – was modelled as a linear function of
dose. The ERR per Sv was estimated by maximum likelihood
(Little et al, 1993) and confidence intervals (CIs) were calculated
and tests for trend in risk with dose were conducted using a score
statistic (Darby and Reissland, 1981; Little et al, 1993). Particular
Table 1 Study population by lifetime dose and first employer
a
Dose range (mSv)
Employer o10.0 10.0  50.0  100.0+
Total number
of workers
Collective dose
(person Sv)
Mean dose
(mSv)
Atomic Weapons Establishment 12240 2157 281 162 14840 122 8.2
British Energy Generation and Magnox Electric Ltd
(England and Wales)
6313 5337 1132 613 13395 323 24.1
British Energy Generation and Magnox Electric Ltd (Scotland) 1894 764 316 181 3155 71 22.7
British Nuclear Fuels plc (BNFL) 19268 11343 3972 5701 40284 2160 53.6
GE Healthcare 2735 664 198 296 3893 122 31.4
HPA-RPD 207 51 15 8 281 4 14.2
MRC Harwell 348 14 2 0 364 1 2.1
Ministry of Defence 56552 5878 1350 1129 64909 522 8.0
Organisations using the HPA Personal Dosimetry Service 249 131 43 63 486 26 54.2
Rolls-Royce Submarines 2213 497 115 15 2840 26 9.0
Science and Technology Facilities Council 1709 600 83 36 2428 30 12.5
UK Atomic Energy Authority (UKAEA) 15038 7966 2362 2300 27666 940 34.0
Total 118766 35402 9869 10504 174541 4348 24.9
aWhere possible, the most recent name for each participating organisation is used here. However, where the historical name provides a more concise means of identifying the
relevant group of workers (eg., for BNFL and UKAEA), this name has been retained.
Mortality and cancer incidence in the third NRRW analysis
CR Muirhead et al
207
British Journal of Cancer (2009) 100(1), 206–212 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yweight was given to one-sided tests for any increase in risk with
increasing dose, but two-sided tests were also conducted.
The cancer incidence analyses used the earliest cancer
mentioned on a registration or a death certificate, except that:
(i) leukaemia, multiple myeloma or lymphoma was selected
ahead of other cancers, with the corresponding earliest date
chosen;
(ii) non-melanoma skin cancer (NMSC) was selected only if no
other malignancies were listed or if death was from a tumour
of an unspecified site or a secondary cancer;
(iii) malignancies were selected in preference to benign conditions.
Points (i) and (iii) were also adopted for the mortality analyses.
RESULTS
Mortality – external analysis
Data were available for 26731 deaths during 3.9 million person-years
of follow-up. Table 2 shows a strong HWE. Without adjustment for
social class, the all-cause SMR was 81 (95% CI 80–82); the
corresponding value for all malignant neoplasms was 84 (95% CI
82–86). The SMR for industrial workers was nearly 50% higher than
that of non-industrial workers, but this difference was less marked
using social class-specific rates. After adjusting for social class, there
was still a strong HWE and, both for all causes and all malignant
neoplasms, the social class-adjusted SMRs were very similar among
men and women (Table 2). The SMRs for all causes and all malignant
neoplasms decreased with increasing duration of radiation work,
particularly for durations of at least 30 years, but there was less
evidence for a decrease after adjusting for social class (Muirhead et al,
2009). All-cause SMRs by first employer generally varied between 63
and 90; the corresponding range using social class-adjusted rates was
72–90 (Muirhead et al, 2009).
For most specific causes of death, SMRs were less than
100 (Supplementary Table S1 on website). For common causes –
particularly those related to smoking – this reduction was usually
statistically significant. There were only a few causes of death with
SMRs above 100. For thyroid cancer (unlagged and lagged SMRs of
110 and 123, respectively), testicular cancer (unlagged 103, lagged
65) and all uterine cancers combined (unlagged 85, lagged 102), the
findings were consistent with national rates. In contrast, pleural
cancer mortality was statistically significantly raised (unlagged
SMR 209, lagged 207).
Mortality – internal analysis
Supplementary Table S2 shows results from analyses that looked
for trends in mortality with external radiation dose. Here, unlike
Supplementary Table S1, the expected numbers were calculated
internally to the cohort. There was borderline evidence of an
increasing trend in total mortality with increasing dose from a
one-sided test (P¼0.049); the corresponding evidence from a
two-sided test was weak (P¼0.098). The evidence for this trend
related mainly to cancer mortality; there was no statistically
significant trend with dose in total mortality from other known
causes, and the estimated ERR was lower than that for all causes
combined. There was evidence of an increasing trend with dose in
mortality from cancer overall from a one-sided test (P¼0.036),
although the evidence from a two-sided test was weaker
(P¼0.073); the ERR per Sv was 0.279 (90% CI 0.02, 0.56).
Omitting leukaemia gave similar results.
Of the 28 non-overlapping groupings of cancers (and consider-
ing all liver cancer other than secondaries rather than primary liver
cancer) in Supplementary Table S2, the estimated ERR per Sv was
positive in 19 and negative in nine instances. Using a one-sided
test at the 5% level, there were statistically significant increasing
trends with dose in mortality from rectal cancer (P¼0.027),
laryngeal cancer (P¼0.026), all uterine cancers (P¼0.016) and
leukaemia excluding CLL (P¼0.042). In contrast, there was no
evidence of a dose trend for all leukaemias combined (one-sided
P¼0.225). Only for all uterine cancers (P¼0.03) was the estimated
trend in mortality with dose significant at the 5% level using a two-
sided test. There was no evidence for any cancer of a decreasing
trend in mortality with increasing dose, using either a one-sided
test for a decreasing trend or a two-sided test.
Among leukaemia subtypes, a one-sided test (P¼0.027)
indicated an increasing trend with dose in chronic myeloid
leukaemia (CML) mortality; the two-sided P-value was 0.054
(Supplementary Table S3). Although not statistically significant,
the estimated ERR per Sv was greater than zero for acute myeloid
(AML) and acute lymphatic leukaemia (ALL) but less than zero for
CLL, even when – as in Vrijheid et al (2008) – a 10-year lag was
used (ERR per Sv o 1.929, 90% CI o 1.93, 1.83).
There was a statistically significant increasing trend with dose in
mortality from all circulatory diseases combined from a one-sided
test (P¼0.03); a two-sided test gave P¼0.059. Much of the
evidence for this trend related to coronary heart disease (CHD)
(one-sided P¼0.053, two-sided P¼0.105). When CHD was
analysed together with other non-malignant diseases that are
Table 2 Standardised mortality ratios (SMRs)
a by broad cause, gender and industrial classification
Number of deaths Unadjusted Social-class adjusted
Gender Industrial classification Observed Expected SMR 95% CI
b SMR 95% CI
All causes
Both All 26731 33014.00 81 80–82 84 83–85
Industrial 18285 19660.37 93 92–94 82 80–83
Non-industrial 8146 12950.43 63 62–64 90 88–92
Men All 25841 31852.94 81 80–82 84 83–85
Women All 890 1161.06 77 72–82 84 79–90
w
2 for heterogeneity in SMR between men and women 2.77 0.01
All malignant neoplasms
Both All 8107 9666.63 84 82–86 82 81–84
Industrial 5394 5640.72 96 93–98 80 78–82
Non-industrial 2622 3905.75 67 65–70 88 85–91
Men All 7752 9229.92 84 82–86 82 80–84
Women All 355 436.71 81 73–90 84 76–93
w
2 for heterogeneity in SMR between men and women 0.36 0.17
aBased on the general population of England and Wales.
bConfidence interval.
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trend with dose. Indeed, there was very strong evidence (two-sided
P¼0.001) that mortality from bronchitis, emphysema and chronic
obstructive disease decreased with increasing dose. For respiratory
diseases unrelated to smoking, the one-sided P-value for an
increasing trend with dose was 0.04, but 0.079 from a two-sided test.
Cancer incidence – internal analysis
For malignancies overall, there were 11165 cases (compared with
7684 deaths) and strong evidence of an increasing trend in total
incidence with dose from both one-sided (P¼0.018) and two-sided
(P¼0.036) tests; ERR per Sv 0.281 (90% CI 0.06, 0.53). Results were
similar when either leukaemia or NMSC was omitted. Of the 29 non-
overlapping groupings of cancers (and considering all liver cancer
other than secondaries rather than primary liver cancer) in
Supplementary Table S4, the estimated ERR per Sv was positive in
19 and negative in 10 instances. There were statististically significant
increasing trends with dose for rectal cancer (one-sided P¼0.02), all
skin cancers (P¼0.01), NMSC (P¼0.02), multiple myeloma
(P¼0.008) and leukaemia excluding CLL (P¼0.03); except for the
last of these, the trends were also significant using a two-sided test.
The trends for all uterine cancers (P¼0.057), thyroid cancer
(P¼0.079) and non-Hodgkin lymphoma (P¼0.081) approached
statistical significance based on a one- (but not a two-) sided test.
There was a statistically significant increasing trend with dose for
endometrial cancer (one-sided P¼0.01). No cancer showed a statis-
tically significant decreasing trend in risk with increasing dose, using
either a one-sided test for a decreasing trend or a two-sided test.
Among leukaemia subtypes, there was evidence from both one-
(P¼0.011) and two-sided (P¼0.022) tests of an increasing trend with
dose in CML incidence (Supplementary Table S3). The estimated ERR
was greater than zero for AML and ALL and less than zero for CLL,
although none of the trends was statistically significant. The estimate
for CLL was still less than zero using a 10-year lag (ERR per Sv  0.337,
90% CI  1.72, 3.1). There was no evidence for an increasing trend with
dose in the incidence of all leukaemias combined, whereas there was
evidence of such a trend after omitting CLL.
Subsidiary analyses
Generally, the main findings did not change greatly when the
format of the analyses was altered (Muirhead et al, 2009). For
mortality from leukaemia excluding CLL but not for incidence, the
variation in the ERR per Sv by attained age was statistically
significant, whereas the data for the grouping of all malignant
neoplasms excluding leukaemia were consistent with a constant
ERR by attained age.
DISCUSSION
General patterns of mortality
As in previous NRRW analyses, overall mortality was lower than
expected from national rates. Although the overall magnitude of
the HWE has changed little between analyses, SMRs have varied
over the follow-up, with indications of a decrease among workers
with at least 30 years radiation work. In the 15-country nuclear
worker study which included many of the workers in NRRW-2,
adjustment was made for duration of radiation work or employ-
ment, so as to allow for any ‘healthy worker survivor effect’, and
led to a sizeable increase in the estimated ERR per Sv for all
cancers other than leukaemia (Cardis et al, 2007; Vrijheid et al,
2007). However, a similar stratification by whether or not the
duration of radiation work was at least 10 years tended to reduce
estimates of the ERR in NRRW-3; furthermore, stratifying by
whether or not the duration was at least 30 years had little impact
(Muirhead et al, 2009).
Leukaemia
Raised risks of leukaemia excluding CLL have been seen among the
Japanese A-bomb survivors, radiotherapy patients and large
groups of radiation workers (UNSCEAR, 2008), including previous
NRRW analyses (Kendall et al, 1992; Muirhead et al, 1999a,b). The
number of deaths from leukaemia excluding CLL studied here is
more than two times that in NRRW-2, whereas the corresponding
number of cases here is nearly 21
2 times the number of deaths in
NRRW-2, hence the 90% CI for the ERR is about 40% narrower
than before, Table 3 and Figure 1 show good agreement in the
estimated ERR per Sv across NRRW-3 (for both mortality and
incidence data), NRRW-2, the 15-country study and the Japanese
A-bomb study. In particular, the findings from NRRW-3 are
consistent with the dose reduction factor of two commonly used
when extrapolating leukaemia risks among the Japanese A-bomb
survivors down to low doses (ICRP, 2007). The 90% CI for the ERR
(Table 3) indicates that the risk of leukaemia excluding CLL is
Table 3 Comparison of estimates of ERR per Sv (and 90% CI) for cancer in the NRRW, the 15-country nuclear worker study and the Japanese A-bomb
survivors
Leukaemia
excluding CLL
All malignant neoplasms
excluding leukaemia
All malignant neoplasms
excluding leukaemia, lung
and pleura cancer
3rd NRRW analysis
Mortality 1.712 (0.06, 4.29) 0.275 (0.02, 0.56) 0.323 (0.02, 0.67)
Incidence 1.782 (0.17, 4.36) 0.266 (0.04, 0.51) 0.305 (0.05, 0.58)
2nd NRRW analysis (Muirhead et al, 1999a,b): mortality 2.55 ( 0.03, 7.16) 0.09 ( 0.28, 0.52) 0.17 ( 0.26, 0.70)
a
15-country nuclear worker study (Cardis et al, 2007): mortality 1.93 (o0, 7.14) 0.97 (0.27, 1.80) 0.59 ( 0.16, 1.51)
Japanese A-bomb survivors
BEIR VII (NRC, 2006): mortality 1.4 (0.1, 3.4)
b 0.26 (0.15, 0.41)
c —
BEIR VII (NRC, 2006): incidence — 0.43
d —
aBased on data for all malignant neoplasms excluding leukaemia and lung cancer.
bBased on the low-dose component of a linear-quadratic dose–response model fitted to
A-bomb data on mortality during 1950–2000. This estimate – as given by Cardis et al (2007) – applies to men exposed at ages of 30 years or more, at 15 years following
exposure.
cBased on fitting a linear dose–response model to A-bomb data on solid cancer mortality during 1950–2000. This estimate – as given by Cardis et al (2007) – applies
to men exposed at ages of 30 years or more, at an attained age of 50 years.
dBased on fitting a linear dose–response model to A-bomb data on the incidence of all solid cancers
other than thyroid and non-melanoma skin cancers during 1958–98. The ERR estimate cited applies to men exposed at ages of 30 years or more, at an attained age of 50 years.
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greater than that estimated by the BEIR VII Committee (NRC,
2006).
As before, the leukaemia subtype showing the strongest evidence
of an association with radiation – from both mortality and
incidence data – is CML. This has also been associated with
radiation in the Japanese A-bomb survivors and some medically
exposed groups (UNSCEAR, 2008). In contrast, there was no
evidence of an association between CLL (either mortality or
incidence) and radiation, even for a 10-year lag. This agrees with
results from many other studies of radiation-exposed groups
(UNSCEAR, 2008).
All cancers other than leukaemia combined
Unlike previous NRRW analyses, NRRW-3 shows a statistically
significant increasing trend with dose in both mortality and
incidence for all malignant neoplasms other than leukaemia. The
findings from the three NRRW analyses are mutually consistent,
but have become progressively more precise. Relative to NRRW-2,
the 90% CI for the ERR per Sv based on mortality (incidence) data
is about 30% (40%) narrower. The NRRW-3 results are also
consistent with those from the 15-country worker study (Table 3),
although the estimated ERR is towards the lower end of the 90% CI
from that study. The latter CI is considerably wider than that for
NRRW-3, reflecting the higher ERR estimate in the 15-country
study and its exclusion of some groups of workers with relatively
high external doses because of potential internal exposure (Cardis
et al, 2007). Stratifying the data according to whether a worker was
ever internally monitored had little impact on our results. To
reduce any possible confounding by smoking or asbestos
exposure, Table 3 also shows results for all malignant neoplasms
other than leukaemia, lung and pleural cancer; here the 90% CI
from NRRW-3 lies within that of the 15-country study, so
demonstrating consistency between the studies and the greater
precision of NRRW-3.
Figure 2 shows good agreement between the ERR mortality
estimates for all malignant neoplasms excluding leukaemia from
NRRW-3 and the Japanese A-bomb study, based on a linear dose–
response model. Similar inferences arise using incidence rather
than mortality data (Table 3) and when excluding lung and pleural
cancer (Figure 3). The 90% CI for all malignant neoplasms
excluding leukaemia (Table 3) indicates that the risk from
occupational radiation exposure is greater than zero but is unlikely
to be more than about two times greater than that estimated from
the A-bomb data using a linear dose–response model. An
important theme in radiation protection is how to estimate cancer
risks at low doses and low-dose rates using results from the A-bomb
survivors, who received a wide range of doses acutely. ICRP (2007)
recommended a dose and dose rate effectiveness factor (DDREF) of
two when extrapolating from high doses and high-dose rates down
to low doses and/or low-dose rates, while the BEIR VII Committee
(NRC, 2006) derived a range for a low-dose extrapolation factor of
(1.1, 2.3) with a central estimate of 1.5 (the BEIR VII risks cited in
Table 3 and in Figures 2 and 3 for cancers other than leukaemia are
based on a linear dose–response model and do not include a low-
dose extrapolation factor). The NRRW-3 data are consistent with
the BEIR VII factor and provide more evidence in favour of a solid
cancer DDREF that is less than two rather than greater than two, but
this latter possibility cannot be ruled out. The risk implied by
NRRW-3 is unlikely to be more than four times greater than the
A-bomb estimate incorporating a DDREF of two.
Specific cancers
There was a statistically significantly increasing trend in multiple
myeloma incidence (but not mortality) with dose. NRRW-3
contains nearly three times the number of myeloma deaths as
NRRW-2 (which reported some evidence of a trend with dose in
mortality), plus additional incident cases. However, the evidence
for a dose trend here relates largely to small numbers among
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Figure 3 Trends with dose in relative risk (and 90% CI) for mortality
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Other populations exposed to radiation have given mixed results
for myeloma (UNSCEAR, 2008). Consequently, the interpretation
of the NRRW-3 results is unclear.
Both NRRW-2 and NRRW-3 found a non-statistically signifi-
cantly raised SMR for thyroid cancer, but no association between
mortality and dose. As thyroid cancers are usually not fatal, the
incidence data should be more informative. Although there was
weak evidence of a trend with external dose in thyroid cancer
incidence (one-sided P¼0.079), this was driven primarily by two
cases with a cumulative dose above 400mSv. Relative to childhood
exposures, adult exposures to either external radiation or radio-
iodine provide less evidence of a raised risk of thyroid cancer and
suggest that any radiation risk would be smaller (UNSCEAR,
2008). The imprecise findings from NRRW-3 are consistent with
this conclusion.
Except for skin cancer, the other cancers for which a dose trend
was found here have rarely been associated with radiation in other
studies (UNSCEAR, 2008). Furthermore, only the findings for
rectal cancer and NMSC were based on large numbers of incident
cases. Although NMSC has been linked to radiation in several
populations (UNSCEAR, 2008), the relevant doses were mainly
above those received here. Furthermore, the registration of NMSC
is known to be poor compared to other cancers and some
differential ascertainment cannot be ruled out; in addition, there is
no information on ultraviolet radiation exposure, a key determi-
nant of NMSC risk. Given that the estimated ERR for rectal cancer
was imprecise and consistent with the corresponding estimate for
all malignant neoplasms other than leukaemia (Supplementary
Table S4), and that many types of cancer were studied, there is
little evidence that rectal cancer is particularly radiosensitive.
Only for pleural cancer was there a statistically significant raised
SMR, but there was no evidence of a dose trend in incidence or
mortality. While there is no information in the NRRW on potential
asbestos exposure, it is highly likely that this raised SMR is due to
asbestos rather than radiation exposure.
Non-cancer mortality
Studies of the Japanese A-bomb survivors and of patients who
received high-dose radiotherapy to the heart have shown raised
rates of heart disease (UNSCEAR, 2008). However, apart from the
A-bomb study, other studies have not provided strong evidence of
raised risks of circulatory diseases below doses of a few Sv
(UNSCEAR, 2008). Occupational studies have yielded mixed
results (e.g. Vrijheid et al, 2007; McGeoghegan et al, 2008).
Furthermore, it was not possible in most worker analyses,
including NRRW-3, to adjust for risk factors for circulatory
diseases.
The estimated ERR per Sv for all circulatory diseases combined
from NRRW-3 (0.251, 90% CI 0.03, 0.49) is comparable with the
A-bomb estimate (Preston et al, 2003). Much of the evidence for a
dose trend arises for CHD, which is particularly influenced by
smoking. For each of CHD, aortic aneurysm, cerebrovascular
disease, all circulatory diseases combined and lung cancer (but not
for smoking-related respiratory diseases), the ratio of observed to
expected numbers of deaths tended to increase with increasing
dose, except for the highest dose group where this ratio falls below
one (Supplementary Table S2). Also, the lack of evidence for a dose
trend after adjusting for duration of radiation work (Muirhead
et al, 2009) suggests that some feature of long-term radiation work
other than radiation itself might influence circulatory disease risk,
although the appropriate lag period is not known. In the absence of
information on confounding factors, interpretation is difficult. The
similar dose patterns in circulatory disease and lung cancer
mortality suggest some confounding by smoking, but the direction
and magnitude of this effect cannot be quantified.
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